Talk Bio – Page 2 – Actionable Insights Powered by AI

Brainomix AI Reveals Hidden Efficacy of ARG-007 in Severe Stroke Patients

1 week ago talkbio0Tagged ARG-007, Brainomix, Brainomix 360, Cerebrovascular accident, neuroprotective, stroke trial

Brainomix; AI; stroke trial; ARG-007; neuroprotective; Argenica Therapeutics; Brainomix 360 Stroke

Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025

1 week ago talkbio0Tagged Asymmetric Septal Hypertrophy, hematologic care, Hematologic Neoplasms, real-world evidence, Real-world Evidence, SOHO

RWE; blood cancer; real-world evidence; ASH 2025; SOHO 2025; hematologic care

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73

1 week ago talkbio0Tagged Antineoplastic Agents, AstraZeneca, Inhibitor, Jacobio Pharma, milestones, pan-KRAS

AstraZeneca; Jacobio Pharma; JAB-23E73; pan-KRAS inhibitor; cancer drug; licensing deal; $100M upfront; $2B milestones

BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion

2 weeks ago talkbio0Tagged Acquisition, Amicus Therapeutics, BioMarin, Galafold, Infrequent, Opfolda, Pombiliti +

BioMarin; Amicus Therapeutics; acquisition; $4.8B; Galafold; Pombiliti; Opfolda; rare diseases

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS’s Camzyos

2 weeks ago talkbio0Tagged Aficamten, Approved, Camzyos, Cytokinetics, Hypertrophic obstructive cardiomyopathy, Myers Squibb, Myqorzo, United States Food and Drug Administration

FDA approval; Cytokinetics; Myqorzo; aficamten; obstructive hypertrophic cardiomyopathy; Bristol Myers Squibb; Camzyos

Bayer’s Finerenone Approved in Japan for Chronic Heart Failure Treatment

2 weeks ago talkbio0Tagged Approved, Bayer, Chronic heart failure, FINEARTS-HF, finerenone, HFmrEF, HFpEF, Japan, Kerendia

Finerenone; Kerendia; Japan approval; chronic heart failure; HFmrEF; HFpEF; Bayer; FINEARTS-HF

White House unveils nine new “most-favored-nation” drug pricing deals

2 weeks ago talkbio0Tagged drug price, eli lilly, Health Policy, MFN, Most-Favored-Nation, Nordisk, Ozempic, pharmaceutical manufacturers, prescription drug costs, Trump administration, U.S., Wegovy, White House

most-favored-nation pricing; MFN; drug pricing; White House; Trump administration; pharmaceutical manufacturers; Ozempic; Wegovy; Eli Lilly; Novo Nordisk; prescription drug costs; US healthcare policy

FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths

2 weeks ago talkbio0Tagged Antibody-Drug Conjugates, Clinical Trials, Daiichi, Deruxtecan, grade 5 ILD, I-DXd, IDeate-Lung02, ifinatamab, Lung Diseases, Interstitial, Merck, Partial, Sankyo, Small cell carcinoma of lung, United States Food and Drug Administration

FDA partial clinical hold; ifinatamab deruxtecan; I-DXd; IDeate-Lung02; Merck; Daiichi Sankyo; small cell lung cancer; interstitial lung disease; grade 5 ILD; antibody-drug conjugate; clinical trial deaths

Recent Biotech News: Altimmune’s Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback

2 weeks ago talkbio0Tagged Altimmune, China, Failed, IMPACT trial, Ipsen, MASH, Obesity, pemvidutide, Phase 2, United States Food and Drug Administration

Altimmune; pemvidutide; MASH; Phase 2b; IMPACT trial; FDA; China obesity; Ipsen; Phase 2 fail

Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study

2 weeks ago talkbio0Tagged Acquisition, brensocatib, Brinsupri, Chronic sinusitis, DPP1 inhibitor, Insmed, mid-stage trial, Nasal inflammation, Nasal Polyps, stocks, Trial failure

Insmed; Brensocatib; Brinsupri; DPP1 inhibitor; chronic rhinosinusitis without nasal polyps; mid-stage trial; Phase 2b; nasal inflammation; trial failure; biotech stocks; INS1148 acquisition